MicroRNA-134-3p inhibits ovarian cancer progression by targeting flap structure-specific endonuclease 1 in vitro

Zhao,Mengshi; Ji,Hongjie; Fu,Qiang; Cheng,Qian; Zhang,Yu; Yang,Yu

doi:10.3892/or.2020.7844

MicroRNA-134-3p inhibits ovarian cancer progression by targeting flap structure-specific endonuclease 1 in vitro

Authors:
- Mengshi Zhao
- Hongjie Ji
- Qiang Fu
- Qian Cheng
- Yu Zhang
- Yu Yang
View Affiliations

Affiliations: School of Minerals Processing and Bioengineering, Central South University, Changsha, Hunan 410083, P.R. China, Department of Obstetrics and Gynecology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: November 10, 2020 https://doi.org/10.3892/or.2020.7844
Pages: 119-128
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer (OC) is one of the most lethal gynecological malignancies in the world. The aim of the present study was to examine the role of microRNA (miR)-134-3p in OC. Reverse transcription-quantitative PCR was used to measure the expression levels of miR-134-3p. Cell Counting Kit-8, TUNEL, flow cytometric and colony formation assays were performed to examine the effects of miR-134-3p on OC cell proliferation. Moreover, wound healing and Transwell assays were performed to examine the effects on migration and invasion. In addition, western blot analyses were used to assess protein expression. Finally, the target genes of miR-134-3p were analyzed by bioinformatics analysis and dual-luciferase reporter assay. The results revealed that miR-134-3p expression was low in OC cells compared with in normal ovarian cells. The overexpression of miR-134-3p decreased cell viability, facilitated cell apoptosis, inhibited cell proliferation and arrested the cell cycle in SKOV-3 and OVCAR-3 cells. Furthermore, transfection using a miR-134-3p mimic inhibited the migration and invasion of SKOV-3 and OVCAR-3 cells, and decreased the protein expression levels of cyclooxygenase-2, matrix metalloproteinase (MMP)2 and MMP9. Bioinformatics analysis indicated that one of the potential target genes of miR-134-3p was flap structure-specific endonuclease 1 (FEN1), which was confirmed by dual-luciferase reporter assay. Moreover, overexpression of miR-134-3p decreased the expression levels of FEN1 in SKOV-3 and OVCAR-3 cells. Additionally, overexpression of FEN1 reversed the effects of the miR-134-3p mimic on the proliferation, migration and invasion of SKOV-3 and OVCAR-3 cells. Overall, the findings of the present study demonstrated that miR-134-3p may inhibit OC cell proliferation, migration and invasion by directly targeting FEN1.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar
2	Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL: Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296. 2018. View Article : Google Scholar
3	Zhang ML, Peng P, Wu CX, Gong YM, Zhang SW, Chen WQ and Bao PP: [Report of breast cancer incidence and mortality in China registry regions, 2008–2012]. Zhonghua Zhong Liu Za Zhi. 41:315–320. 2019.(In Chinese).
4	Marth C, Reimer D and Zeimet AG: Front-line therapy of advanced epithelial ovarian cancer: standard treatment. Ann Oncol. 28 (Suppl 8):pp. viii36–viii39. 2019, simplehttps://doi.org/10.1093/annonc/mdx450 View Article : Google Scholar
5	Bieg D, Sypniewski D, Nowak E and Bednarek I: MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Arch Gynecol Obstet. 299:1077–1087. 2019. View Article : Google Scholar
6	Yang B, Sun L and Liang L: MiRNA-802 suppresses proliferation and migration of epithelial ovarian cancer cells by targeting YWHAZ. J Ovarian Res. 12:1002019. View Article : Google Scholar
7	Ding Y, Fang Q, Li Y and Wang Y: Amplification of lncRNA PVT1 promotes ovarian cancer proliferation by binding to miR-140. Mamm Genome. 30:217–225. 2019. View Article : Google Scholar
8	Fan B, Chen LP, Yuan YH, Xiao HN, Lv XS and Xia ZY: MiR-15a-3p suppresses the growth and metastasis of ovarian cancer cell by targeting Twist1. Eur Rev Med Pharmacol Sci. 23:1934–1946. 2019.
9	Zuo Y, Zheng W, Liu J, Tang Q, Wang SS and Yang XS: MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells. Neoplasma. 67:93–101. 2020. View Article : Google Scholar
10	Zhang X, Xin G and Sun D: Serum exosomal miR-328, miR-575, miR-134 and miR-671-5p as potential biomarkers for the diagnosis of Kawasaki disease and the prediction of therapeutic outcomes of intravenous immunoglobulin therapy. Exp Ther Med. 16:2420–2432. 2018.
11	Chen CL, Zhang L, Jiao YR, Zhou Y, Ge QF, Li PC, Sun XJ and Lv Z: miR-134 inhibits osteosarcoma cell invasion and metastasis through targeting MMP1 and MMP3 in vitro and in vivo. FEBS Lett. 593:1089–1101. 2019. View Article : Google Scholar
12	Qin Q, Wei F, Zhang J, Wang X and Li B: miR-134 inhibits non-small cell lung cancer growth by targeting the epidermal growth factor receptor. J Cell Mol Med. 20:1974–1983. 2016. View Article : Google Scholar
13	Qi A, Han J, Jia F and Liu C: miR-3175 and miR-134 affect proliferation, invasion and apoptosis of glioma cells through PI3K/AKT signaling pathway. J BUON. 24:2465–2474. 2019.
14	Ma Z, Li K, Chen P, Pan Q, Li X and Zhao G: MiR-134, mediated by IRF1, suppresses tumorigenesis and progression by targeting VEGFA and MYCN in osteosarcoma. Anticancer Agents Med Chem. 20:1197–1208. 2020. View Article : Google Scholar
15	Greene AL, Snipe JR, Gordenin DA and Resnick MA: Functional analysis of human FEN1 in Saccharomyces cerevisiae and its role in genome stability. Hum Mol Genet. 8:2263–2273. 1999. View Article : Google Scholar
16	Gary R, Park MS, Nolan JP, Cornelius HL, Kozyreva OG, Tran HT, Lobachev KS, Resnick MA and Gordenin DA: A novel role in DNA metabolism for the binding of Fen1/Rad27 to PCNA and implications for genetic risk. Mol Cell Biol. 19:5373–5382. 1999. View Article : Google Scholar
17	Gomes XV and Burgers PM: Two modes of FEN1 binding to PCNA regulated by DNA. EMBO J. 19:3811–3821. 2000. View Article : Google Scholar
18	Nikolova T, Christmann M and Kaina B: FEN1 is overexpressed in testis, lung and brain tumors. Anticancer Res. 29:2453–2459. 2009.
19	Lu X, Liu R, Wang M, Kumar AK, Pan F, He L, Hu Z and Guo Z: MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer. Oncogene. 39:234–247. 2020. View Article : Google Scholar
20	20. Dong S, Xiao Y, Ma X, He W, Kang J, Peng Z, Wang L and Li Z: miR-193b Increases the chemosensitivity of osteosarcoma cells by promoting FEN1-mediated autophagy. OncoTargets Ther. 12:10089–10098. 2019. View Article : Google Scholar
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
22	Zhang YY, Li P, Zhu MZ, Guo Y and Yang J: LINC01308 accelerates the malignant progression of ovarian cancer by binding to miRNA-506. Eur Rev Med Pharmacol Sci. 23:3253–3260. 2019.
23	Pan JY, Zhang F, Sun CC, Li SJ, Li G, Gong FY, Bo T, He J, Hua RX, Hu WD, et al: miR-134: A human cancer suppressor? Mol Ther Nucleic Acids. 6:140–149. 2017. View Article : Google Scholar
24	Qin Q, Wei F, Zhang J and Li B: miR-134 suppresses the migration and invasion of non-small cell lung cancer by targeting ITGB1. Oncol Rep. 37:823–830. 2017. View Article : Google Scholar
25	Peng SY, Tu HF, Yang CC, Wu CH, Liu CJ, Chang KW and Lin SC: miR-134 targets PDCD7 to reduce E-cadherin expression and enhance oral cancer progression. Int J Cancer. 143:2892–2904. 2018. View Article : Google Scholar
26	Chang C, Liu T, Huang Y, Qin W, Yang H and Chen J: MicroRNA-134-3p is a novel potential inhibitor of human ovarian cancer stem cells by targeting RAB27A. Gene. 605:99–107. 2017. View Article : Google Scholar
27	Shuang T, Wang M, Shi C, Zhou Y and Wang D: Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells. FEBS Lett. 589 (20 Pt B):3154–3164. 2015. View Article : Google Scholar
28	Prasad R, Dianov GL, Bohr VA and Wilson SH: FEN1 stimulation of DNA polymerase beta mediates an excision step in mammalian long patch base excision repair. J Biol Chem. 275:4460–4466. 2000. View Article : Google Scholar
29	Storici F, Henneke G, Ferrari E, Gordenin DA, Hübscher U and Resnick MA: The flexible loop of human FEN1 endonuclease is required for flap cleavage during DNA replication and repair. EMBO J. 21:5930–5942. 2002. View Article : Google Scholar
30	Zeng X, Qu X, Zhao C, Xu L, Hou K, Liu Y, Zhang N, Feng J, Shi S, Zhang L, et al: FEN1 mediates miR-200a methylation and promotes breast cancer cell growth via MET and EGFR signaling. FASEB J. 33:10717–10730. 2019. View Article : Google Scholar
31	Abdel-Fatah TM, Russell R, Albarakati N, Maloney DJ, Dorjsuren D, Rueda OM, Moseley P, Mohan V, Sun H, Abbotts R, et al: Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer. Mol Oncol. 8:1326–1338. 2014. View Article : Google Scholar